A Severe COVID-19-associated hNTPDase2 Variant is Enzymatically Inactive

In the microscopic world of our bodies, cells constantly communicate using chemical signals, some of which are built from molecules called nucleotides. Among these, a molecule known as ATP acts as a powerful signal that can trigger inflammation, essentially sounding an alarm to summon the immune system to a site of injury or infection. Under normal circumstances, the body has a sophisticated cleanup crew of enzymes that break down these signals once they have done their job, preventing the alarm from ringing too loudly or for too long. One such enzyme, called hNTPDase2, sits on the surface of certain cells and acts like a specialized pair of scissors, snipping apart ATP and similar molecules to keep their levels in check. When this system works correctly, inflammation is controlled and contained. However, when the levels of these signaling molecules get too high, as seen in severe cases of respiratory illness, the resulting overactive immune response can damage the very tissues it is trying to protect.

Researchers have long known that patients suffering from severe forms of COVID-19 often exhibit dangerously high levels of these extracellular signaling molecules. A recent study published by a team at Université Laval in Canada investigates a specific genetic variation found in some of these patients that might explain why their bodies failed to regulate this process. The scientists focused on a tiny error in the genetic code for the hNTPDase2 enzyme, a mutation that had been flagged in medical databases as potentially harmful. By recreating this specific genetic variant in the laboratory, the team discovered that the mutation completely destroys the enzyme's ability to function. Their findings suggest that individuals carrying this genetic flaw lack the molecular scissors necessary to clear away excess ATP, potentially leaving their airways in a state of uncontrolled inflammation that worsens the severity of the disease.

The study began with a close examination of a specific genetic sequence found in patients with severe COVID-19. The researchers identified a single missing letter in the DNA instructions for the hNTPDase2 enzyme. In the language of genetics, this small deletion causes a shift in how the entire remaining sequence is read, much like removing a single letter from a sentence and changing the meaning of every word that follows. This shift leads to the creation of a premature stop signal, causing the body to build a protein that is significantly shorter than the full-length version. Instead of the usual 495 building blocks, or amino acids, the mutated protein stops at 408. This truncation is critical because it cuts off the very end of the protein, removing a section known as the C-terminal transmembrane domain and several other parts that are essential for the enzyme's job.

To understand exactly what this genetic error meant for the enzyme's function, the scientists recreated the mutation in a laboratory setting. They used a technique called site-directed mutagenesis to introduce the exact same single-letter deletion into a DNA sequence they had cloned, creating a version of the enzyme they called hN2COV. They then inserted this genetic code into living cells, specifically a type of hamster cell line often used for protein production, to see if the cells would build the faulty enzyme. To ensure they could track the protein, they added a small molecular tag to the end of both the normal and the mutated versions. The team confirmed that the cells were indeed producing the mRNA instructions for the mutant protein, proving that the genetic code was being read. However, when they looked for the actual protein using antibodies designed to recognize the normal enzyme, they could not find it. This suggested that the mutated protein was either unstable or structurally different enough that the standard detection tools could not recognize it.

The researchers then turned to a more direct method to see if the mutant enzyme could still do its work. They measured the enzyme's ability to break down ATP, ADP, UTP, and UDP, the four main molecules it is supposed to process. Using a standard chemical test that detects the release of phosphate when these molecules are broken down, they compared the performance of the normal enzyme against the mutant version. The results were stark and definitive. The normal enzyme efficiently broke down ATP and UTP, just as expected. In contrast, the mutant hN2COV showed no detectable activity whatsoever. It was completely unable to break down any of the four substrates. This confirmed that the mutation was not just a minor glitch but a total loss of function, rendering the enzyme useless.

The reason for this total failure lies in the specific parts of the protein that were lost. The missing tail of the enzyme contained a crucial amino acid called Cysteine 399, which is known to form a chemical bridge with another part of the protein to hold its shape together. Without this bridge, the enzyme cannot fold correctly. The missing section also included a site where sugar molecules are normally attached, a process essential for the enzyme's full activity, and other residues that help the enzyme grab onto its target molecules. The team noted that the mutation replaced the missing natural tail with a short, random string of 18 new amino acids that do not belong to any known protein family, offering no chance that the enzyme could gain a new function to compensate for the loss.

The implications of this finding extend beyond the laboratory bench. While the enzyme is not found in the blood cells that circulate throughout the body, it is present in the lining of the respiratory tract, including the nose and bronchi. This is the exact location where the virus that causes COVID-19 first enters and attacks the body. In other respiratory infections, such as the flu, high levels of ATP in the airways have been linked to severe swelling and fluid buildup. The researchers propose that in patients with this specific genetic mutation, the lack of functional hNTPDase2 in the airways means that the excess ATP generated during the viral infection cannot be cleared away. This accumulation likely keeps the immune alarm ringing too loudly, leading to a more aggressive and damaging inflammatory response that contributes to the severity of the illness.

The study does not claim that this mutation is the sole cause of severe COVID-19, nor does it suggest that every patient with severe symptoms carries this specific genetic flaw. Instead, the work provides a clear mechanistic explanation for why the disease might be more severe in a subset of individuals. By demonstrating that this specific variant is enzymatically inactive, the researchers have identified a potential biological vulnerability. The findings suggest that the disruption of nucleotide signaling in the airways could be a local factor that aggravates the disease, pointing toward a specific area where the body's natural defense mechanisms have failed. This insight offers a clearer picture of the biological landscape in severe cases and highlights the importance of genetic variations in how individuals respond to respiratory infections.